Oncology Drugs - Zambia

Zambia

The projected revenue for the Oncology Drugs market in Zambia is expected to reach US$26.30m in 2024.
Furthermore, it is anticipated that the revenue will show an annual growth rate (CAGR 2024-2029) of 7.64%, resulting in a market volume of US$38.01m by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$103,900.00m in 2024.
The demand for advanced oncology drugs in Zambia has been steadily increasing due to the rising incidence of cancer cases in the country.

Key regions: France, Europe, United Kingdom, Brazil, India

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for oncology drugs in Zambia has been on the rise in recent years.

Customer preferences: Zambian customers have shown a preference for oncology drugs that are affordable and easily accessible. They also prefer drugs that have minimal side effects and are effective in treating the specific types of cancer prevalent in the region.

Trends in the market: One of the major trends in the Zambian oncology drugs market is the increasing awareness of cancer and the importance of early detection. This has led to a growing demand for screening and diagnostic tests, as well as a greater need for effective treatment options. Another trend is the emergence of innovative therapies such as immunotherapy, which have shown promising results in the treatment of various types of cancer.

Local special circumstances: Zambia faces several challenges in the oncology drugs market, including a lack of infrastructure and resources, limited access to healthcare in rural areas, and a shortage of skilled healthcare professionals. Additionally, there is a high prevalence of HIV/AIDS in the country, which increases the risk of certain types of cancer.

Underlying macroeconomic factors: Zambia's economy has been growing in recent years, driven by the mining and agriculture sectors. However, the country still faces significant challenges, including high levels of poverty and unemployment. The government has made efforts to improve the healthcare system, but funding remains limited. The high cost of oncology drugs and the limited availability of health insurance coverage also pose challenges for patients seeking treatment.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.